This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The UK pharma sector should emerge from COVID-19 with a great deal of goodwill in the bank, especially after rapidly developing vaccines that are helping to steer the world out of the pandemic. There are plans by the UK health sector containing bold proposals to modernise patient information storage.
Practical examples of this include healthcare professionals using VR to learn various medical procedures or for the technology to be used to teach broader society about public health issues, such as the importance of vaccination. When both ‘treatments’ were combined, the vaccination intention increased even further. The more you know.
In early 2020, health officials were cautious about forecasting a COVID-19 vaccine timeline to the public, as vaccine discovery was a historically laborious process that took years (if not decades). Yet a successful COVID-19 vaccine gained emergency approval in just 11 months, a blistering pace that likely saved millions of lives.
The pharmaceutical industry has sometimes been a laggard in terms of digital maturity, but the COVID-19 crisis has provided companies the impetus to rapidly implement the most cutting-edge technologies. There are exciting developments happening for AI in healthcare – from drug discovery to diagnostics and care delivery.
The number of industry clinical trials initiated in the UK, per year, fell by 41 percent from 2017 to 2021, according to the latest annual report on clinical research from the Association of the British Pharmaceutical Industry ( ABPI ).
Having previously spoken with Dr Mullen three years ago when she was country medical director for the UK & Ireland at GSK – on the topic of patient centricity and embedding that focus within the core of a pharmaceuticalcompany – our recent interview provided some interesting insights into the changing landscape of the industry.
Dr João Gonçalves PhD presents his pick for this year’s top five pharmacy innovations, illustrating how they set new standards for patientcare and pharmaceutical development. Researchers have now adapted mRNA vaccines to target a range of other infectious diseases such as influenza, HIV and Zika.
Despite this, pharmaceuticalcompanies have not won over public trust. A recent study found that only 48% of participants expressed trust in pharmaceuticalcompanies. This lack of trust in such a crucial industry can lead to decreased compliance, poor treatment adherence, and negative health outcomes for patients.
Artificial intelligence can assist governments and healthcare institutions in combating pandemics , including monitoring and predicting outbreaks, speeding up diagnostics and research, repurposing existing drugs, and even accelerating vaccine design and development. AI in life sciences is a lot more than just a tool for optimization.
More recently, the rapid development of Moderna’s COVID-19 vaccine, which used many of the principles of synthetic biology, is yet more proof that this is an area on the cusp of the pharmaceutical R&D mainstream. Funding radical innovation. About the interviewee.
110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
For the pharmaceutical industry, disorder in the supply chain can be catastrophic especially when it comes to life saving and sustaining drugs. Global shortages of critical drugs are a growing issue, as demonstrated by the recent challenges around cold chains for COVID vaccines. The CMO solution.
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Telemedicine rose dramatically in many countries, providing a route to managing ongoing care which was a lifeline for many patients.
With the adoption of digital technologies gaining traction in many industries, pharmaceuticalcompanies must take advantage of digitalisation within its research and development (R&D) sector. This approach facilitates a comprehensive understanding of medical information and enhances the management of patientcare.
Many patients and healthcare providers now meet online, and some clinical studies can be conducted virtually, with wearables and AI enabling data collection and treatment adaptation. The aim is to work with start-up companies to generate ideas for digital therapeutics, patient support apps, and boosting research and development.
For more than 240 years, Takeda has focused on delivering transformative treatments in the therapeutic areas of gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
Recent proposals by the US government to impose tariffs on pharmaceutical imports from key trade partners including the EU, China, India, Canada, and Mexico have raised concerns about market instability. 1 Here, we explore the potential impact of tariffs on pharmaceutical supply chains, pricing, investment and industry strategy.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content